Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
Duncan R. McKenzie, Miguel Muñoz‐Ruiz, Leticia Monin, Thanussuyah Alaguthurai, Thomas Lechmere, Sultan Abdul-Jawad, Carl Graham, Emily Pollock, Rosalind Graham, Kamila Sychowska, Jeffrey Seow, Catherine Tremain, Charalampos Gousis, Clara Domingo‐Vila, Jack Cooper, Jennifer Vidler, Kasia Owczarczyk, Angela Swampillai, Hartmut Kristeleit, Michael H. Malim, Paul Fields, Piers Patten, Sophie Papa, Bernard V. North, Timothy Tree, Katie J. Doores, Adrian Hayday, Sheeba Irshad
Topics & Concepts
MedicineSeroconversionVaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)CancerImmune systemImmunologyImmunogenicity2019-20 coronavirus outbreakCancer vaccineImmunotherapyVirologyAntibodyInternal medicineOutbreakDiseaseInfectious disease (medical specialty)SARS-CoV-2 and COVID-19 ResearchCOVID-19 and healthcare impactsCOVID-19 Clinical Research Studies